BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Real-time BOERSE MUENCHEN 05:46:21 2024-07-18 am EDT | ||
| 1,033 EUR | +0.05% |
|
| Current month | -0.16% | ||
| 1 month | +0.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-18 | 1,033 | +0.05% |
| 24-07-17 | 1,032 | -0.33% |
| 24-07-16 | 1,035 | +0.02% |
| 24-07-15 | 1,035 | +0.05% |
| 24-07-12 | 1,035 | +0.04% |
Real-time BOERSE MUENCHEN
Last update July 18, 2024 at 05:46 am EDT
More quotesStatic data
| Product type | Certificati Bonus e Protezione parz. |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CH9 |
| ISIN | DE000HD0CH94 |
| Date issued | 2023-11-01 |
| Strike | 1,050 kr |
| Maturity | 2024-12-20 (156 Days) |
| Parity | 1 : 1 |
| Emission price | 826.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,035 € |
|---|---|
| Lowest since issue | 793.2 € |
| Spread | 1.03 € |
| Spread % | 0.10% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
919
DKK
Average target price
956.8
DKK
Spread / Average Target
+4.11%
- Stock Market
- Certificates
- Certificat